Metagenomi Reports Curative FVIII Data, Plans 4Q 2026 IND Submission
Metagenomi Therapeutics completed a pre-IND meeting after MGX-001 preclinical data demonstrated curative FVIII activity in non-human primates and plans an IND submission in 4Q 2026. The Company ended 2025 with $160.8 million in cash and securities, funding operations through 4Q 2027.
1. Preclinical Milestone for MGX-001 Hemophilia A
Metagenomi Therapeutics advanced its lead hemophilia A program by completing a pre-IND meeting after MGX-001 preclinical studies demonstrated curative FVIII activity in non-human primates, indicating potential for a one-time, durable treatment.
2. Regulatory Submission Timeline
The Company remains on track to file global IND applications in the fourth quarter of 2026 and, subject to regulatory clearance, initiate clinical trials of MGX-001 in 2027.
3. Financial Position and Runway
As of December 31, 2025, the Company held $160.8 million in cash, cash equivalents, and marketable securities, providing funding for operations through the fourth quarter of 2027 without immediate financing needs.
4. Corporate Rebranding and Strategic Focus
A corporate name change to Metagenomi Therapeutics, Inc. reflects a sharpened strategic focus on advancing the MGX-001 hemophilia A program and expanding genome-editing treatment candidates for secreted protein deficiencies and cardiometabolic diseases.